Drug Profile

CX 2043

Alternative Names: Anti-EpCAM antibody drug conjugate; Anti-EpCAM probody drug conjugate; CX-2043

Latest Information Update: 14 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CytomX Therapeutics; ImmunoGen
Developer CytomX Therapeutics
Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

12 Feb 2024 ImmunoGen has been acquired by AbbVie
13 Jul 2022 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
20 Jan 2021 CytomX Therapeutics plans a phase I trial for Solid tumours (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com